René Adam

TL;DR: LT may offer a benefit for highly selected patients with cirrhosis and unresectable iCCA/cHCC‐CCA having tumors ≤5 cm and efforts should be made to evaluate tumor differentiation, and these results need to be confirmed prospectively in a larger population.

TL;DR: The addition of cetuximab to chronotherapy allowed safe and effective therapeutic control of metastases, including their complete resection, despite previous failure of several treatment regimens.

TL;DR: In patients with CLM and elevated tumor markers, biological response is as accurate as CT imaging to assess “clinical” response to chemotherapy, and CA19.9 evolution has even better prognostic value than does radiological response.

TL;DR: In this article, the authors defined robust benchmark values for the surgical treatment of perihilar cholangiocarcinomas (PHC) to enable unbiased comparisons and analyzed consecutive patients undergoing major liver surgery for PHC in 24 highvolume centers in 3 continents over the recent 5-year period (2014-2018) with a minimum follow-up of 1 year in each patient.

TL;DR: This first large‐scale European snapshot study clearly shows that both LT candidates and recipients are at a high risk for COVID‐19, and plead for an early and pro‐active screening of CO VID‐19 symptoms in these populations.